Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Central Pharmaceuticals has a quick ratio of 1.01. It generally indicates good short-term financial strength.
The historical rank and industry rank for Central Pharmaceuticals's Quick Ratio or its related term are showing as below:
DHA:CENTRALPHL'
s Quick Ratio Range Over the Past 10 Years
Min: 1.01 Med: 1.14 Max: 2.33
Current: 1.01
During the past 13 years, Central Pharmaceuticals's highest Quick Ratio was 2.33. The lowest was 1.01. And the median was 1.14.
DHA:CENTRALPHL's Quick Ratio is ranked worse than 65.03% of 998
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs DHA:CENTRALPHL: 1.01
Central Pharmaceuticals (DHA:CENTRALPHL) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Central Pharmaceuticals Quick Ratio Related Terms
Central Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:CENTRALPHL vs ZTS, UTHR, VTRS: Quick Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Central Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Central Pharmaceuticals Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Central Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Central Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Central Pharmaceuticals's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Central Pharmaceuticals (DHA:CENTRALPHL) has a Quick Ratio of 1.01 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Central Pharmaceuticals and its competitors. This is 11% below median its historical median of 1.14. Over the past decade, Central Pharmaceuticals' Quick Ratio has ranged from 1.01 to 2.33. According to the industry distribution chart, Central Pharmaceuticals ranks #649 out of 998 companies in the Drug Manufacturers industry, placing it in the top 65%.
Is Central Pharmaceuticals' Quick Ratio too high?
Central Pharmaceuticals' current Quick Ratio of 1.01 is 11% below median its 10-year median of 1.14. Over the past 10 years, this metric has ranged from a low of 1.01 to a high of 2.33. The Drug Manufacturers industry median Quick Ratio is 1.45. Central Pharmaceuticals' value of 1.01 is 30.3% below this industry median. Based on the distribution chart, Central Pharmaceuticals ranks #649 out of 998 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Central Pharmaceuticals has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Central Pharmaceuticals' Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Central Pharmaceuticals ranks #649 out of 998 companies for Quick Ratio. This places Central Pharmaceuticals in the lower half of its industry. The industry median Quick Ratio is 1.45. Central Pharmaceuticals' value of 1.01 is 30.3% below this benchmark. Historically, Central Pharmaceuticals' own Quick Ratio has ranged from 1.01 to 2.33 over the past decade. While the company's 10-year median is 1.14 vs. the industry median of 1.45, Central Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Central Pharmaceuticals's current Quick Ratio of 1.01 is 30.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Central Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Central Pharmaceuticals's current Quick Ratio is 1.01, which is 11% below median its own 10-year median of 1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Central Pharmaceuticals (DHA:CENTRALPHL) is currently considered Fairly Valued. The stock's GF Value™ is BDT12.04, compared to a current price of BDT11.50 — trading 4.5% below its estimated fair value. The current Quick Ratio is 1.01, which is 11% below median its 10-year median of 1.14 and 30.3% below the Drug Manufacturers industry median of 1.45. Central Pharmaceuticals' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Central Pharmaceuticals (DHA:CENTRALPHL), the current Quick Ratio is 1.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Central Pharmaceuticals (DHA:CENTRALPHL) Overvalued in 2026?
Based on GuruFocus' analysis, Central Pharmaceuticals stock appears to be undervalued.
The current stock price of BDT11.50 is trading 4.5% below its estimated GF Value™ of BDT12.04.
GuruFocus considers Central Pharmaceuticals to be Fairly Valued.
Key valuation signals for DHA:CENTRALPHL:
Quick Ratio: 1.01 (11% below median its 10-year median of 1.14)
GF Value™: BDT12.04 vs. price of BDT11.50 (4.5% below fair value)
Industry Position: 30.3% below the Drug Manufacturers median (#649 of 998)
No single metric tells the full story. See the DHA:CENTRALPHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Central Pharmaceuticals Ltd is engaged in the manufacturing and marketing of medicines in Bangladesh. The company manufactures finished pharmaceutical formulations, including tablets, capsules, liquids, ointments, and injectables, covering therapeutic areas such as anti-infectives, cardiovascular treatments, pain management, and gastrointestinal remedies. It conducts production and sales exclusively in the domestic market through its own facilities and distribution network. The company generates revenue from the sales of its pharmaceutical preparations.
66GF Score
Get the complete analysis for DHA:CENTRALPHL
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:CENTRALPHL has been successfully added to your 
